FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6.65 USD
-0.18 (-2.71%)
ENTA Financial Statements
Quarter
2025 Q1
2024 Q4
2024 Q3
2024 Q2
Total Revenue
16.96M
14.61M
17.97M
17.05M
Cost of Revenue
0
0
0
621k
Gross Profit
16.96M
14.61M
17.97M
16.43M
Operating Expenses
40.5M
44.46M
42.16M
49.82M
Research and Development
27.66M
30.78M
28.74M
35.59M
Selling, General & Administrative Expenses
12.85M
13.68M
13.41M
14.23M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
12.85M
13.68M
13.41M
14.23M
Other Expenses
0
0
0
0
Operating Income
-23.54M
-29.85M
-24.18M
-32.77M
Total Other Income/Expenses Net
837k
668k
1.13M
1.25M
Income Before Tax
-22.71M
-29.19M
-23.05M
-31.52M
Income Tax
-416k
-363k
-395k
-363k
Net Income
-22.29M
-28.82M
-22.66M
-31.16M
Basic EPS
-1.05
0
-1.07
-1.47
EPS Diluted
-1.05
0
-1.07
-1.47
Basic Average Shares
21.24M
0
21.18M
21.17M
Diluted Average Shares
21.24M
0
21.18M
21.17M
EBITDA
-19.86M
-26.13M
-20.1M
-28.34M
Retained Earning Schedule
Quarter
2025 Q1
2024 Q4
2024 Q3
2024 Q2
Retained Earnings (Previous Year)
-323.04M
-294.22M
-271.56M
-240.4M
Net Income
-22.29M
-28.82M
-22.66M
-31.16M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-345.33M
-323.04M
-294.22M
-271.56M
Other Distributions
-22.29M
-28.82M
-22.66M
-31.16M
PPE Schedule
Quarter
2025 Q1
2024 Q4
2024 Q3
2024 Q2
Gross PPE
77.04M
73.35M
66.26M
58.37M
Annual Depreciation
889k
479k
594k
621k
Capital Expenditure
-8.74M
-8.95M
-6.54M
-1.67M
Net PPE
84.9M
81.82M
72.21M
59.42M
Intangible and Goodwill Schedule
Quarter
2025 Q1
2024 Q4
2024 Q3
2024 Q2
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
